KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Repurchased
Ratios

Charles River Laboratories International (CRL) EBIAT (2016 - 2025)

Charles River Laboratories International (CRL) has 17 years of EBIAT data on record, last reported at -$276.3 million in Q4 2025.

  • For Q4 2025, EBIAT fell 28.32% year-over-year to -$276.3 million; the TTM value through Dec 2025 reached -$142.6 million, down 742.13%, while the annual FY2025 figure was -$142.2 million, 740.29% down from the prior year.
  • EBIAT reached -$276.3 million in Q4 2025 per CRL's latest filing, down from $55.6 million in the prior quarter.
  • Across five years, EBIAT topped out at $189.0 million in Q4 2023 and bottomed at -$276.3 million in Q4 2025.
  • Average EBIAT over 5 years is $62.0 million, with a median of $90.7 million recorded in 2021.
  • Peak YoY movement for EBIAT: skyrocketed 45.49% in 2022, then tumbled 213.95% in 2024.
  • A 5-year view of EBIAT shows it stood at $139.8 million in 2021, then surged by 32.25% to $184.9 million in 2022, then rose by 2.18% to $189.0 million in 2023, then crashed by 213.95% to -$215.3 million in 2024, then dropped by 28.32% to -$276.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBIAT were -$276.3 million in Q4 2025, $55.6 million in Q3 2025, and $52.7 million in Q2 2025.